Most Recent
The High Court won't hear Bayer's appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company's claim the decision has "profound" consequences for drug R&D.
Pharmaceutical giant Lundbeck has resolved its battle with Novartis unit Sandoz over top-selling drug Lexapro, a battle that has raged for years and across multiple courts.
Pharmaceutical giant Novartis is challenging the loss of its case against Sydney-based generics company Pharmacor over a patent for heart medication Entresto.
The Full Federal Court won't give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a "commercial outcome for a patentee".
A judge has slammed Novartis for putting forward four "overlapping" experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown three of those experts out of an upcoming joint conferral, known as a "hot tub".
The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck's patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.
The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an "untenable" patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.